Reddit Posts
Insiders buying up small-cap Biotech Stock ($BCAB, $SYRS, $PLSE, $ERAS, $LQDA, $CATX)
Mentions
how do you know which stock u should invest? like u guys giving crazy ideas here SCX NMRA were gold, how do u analyze it? im willing to pay for the knowledge
NMRA potential to climb back to 2.5 high shorrlyv
GUTS is very similar to NMRA. Look what happened to NMRA when their trial drug failed.
Yes did ride NMRA for sometime but now out. Need to check the status again on that
Any visibility of what is on for NMRA and KROS? Been in those stocks for sometime now, buying at all the dips but waiting for a trigger.
It is until it ain’t! Same was said about NMRA and FTHM.
Lol MMs gotta make the market move somehow. Either way, these will pay same way that FTHM and NMRA did!
These are pure technical analysis plays. They could sell bootyhole crumbs and if the play fits my criteria, the risk to reward is a no brainer. Everyone said the same thing about NMRA and FTHM. Let’s see what happens 🧨
That’s what ppl said about NMRA and FTHM. It is until it ain’t and when it happens everyone wants to ask how and what’s next. Let’s see what happens🧨
lol you had me in the first half. Currently premium is 0.05 the lowest it’ll ever get. Low float with volume rising and breaking structure. All we need is a pop to .10 premium to get 100% gainz minimum. A rally to 2.50 is very likely due to the way price action and volume is action right now mixed with the low float. Out of NMRA, FTHM and GTIM, GTIM has the lowest float at under 8mil. NMRA had 120mil, FTHM had 15mil. GTIM is a ticking time bomb. We will sell into the spike 💰
ABOS, NMRA and COSM for this week
NMRA, good price today
It is until it ain’t! Same was said about NMRA. The signs are subtle but they are there 🧨
NMRA going back to $10+?
I’ll trade FTHM the same way I trade all the stocks I pick. Technical analysis and psychological markers. It ended red today, and that’s what I wanna see. On the daily chart look at this big green candles and look at the volume on those candles, it’s massive. The next 2 candles are red with decent volume but not more than the green ones. This is a healthy pullback. Don’t enter yet. Let’s wait a couple days to see what it does here. It’s right around support line after breaking above the inverted head and shoulders. What I’m looking for here is if there is still demand there. The next couple candles will let us know and once I get that confirmation, that’s when I’ll buy. The calls I’m looking at are the furthest out calls with the cheapest price. This lowers risk and raises reward. For example, look at my picture on this post. I bought the NMRA calls yesterday but for an expiry of September. I never expect to hold for that long and I never do. I sell into the price spikes. For the psychological part, FTHM will rise with rate cuts. There’s been talk that feds will cut rates. Even if they don’t, I anticipate that FTHM will rise bcuz of ppl thinking that Feds will cut rates. So then they’ll buy into stocks like FTHM. It’s also near all time lows right now and its float is 15mil which is very attractive. When this starts to move, it’s gonna go fast.
Haha no way man. The chart and the volume don’t lie. Look at the daily chart. I saw the same things on this chart as with NMRA. The next couple trading days will really be the confirmation
Lmao that’s what they said about NMRA too and now look at it. Everyone doubts until it’s there, then they ask how. Bitch I literally told you! Come on mane
Their Facebook page? Lol. Everyone also doubted NMRA when I told them but all good!
I don’t have a price target for FTHM. I usually just watch price action and the volume in the daily chart. NMRA is breaking out but low volume. I think it’ll continue into tmrw where I’ll sell but if the candle tmrw doesn’t come with big volume, it’s likely coming down for a bit
Similar setup to NMRA. The Greeks were shit until they weren’t 🤷
Sounds good mane. GL in $RAYA. Also check out NMRA calls but that one might be gone already. My calls are up 5,200% on NMRA rn. Next one that’s gonna go is FTHM I think. It’s currently testing support on the daily. Big volume on the buys and low volume selling. Waiting for confirmation until I load on the calls. GL mane
That’s fine. There are just much better plays of risking $180. For example, FTHM calls, NMRA calls, INMB calls. Those will pay much more and in much less time
All these are doing real well for me lately ANPA FFAI SBET PLUG OPAD PGY NMRA
Guess, I was wrong. My DD here with why I did not buy: https://www.notion.so/DD-Neumora-Therapeutics-NMRA-215b7cf3b53c80d4b600c3755ef6356f.
NMRA looks fantastic last week.
Good luck man. I put 95% of my IRA with Robinhood into CSPs on $NMRA and lost my ass. I own 4,000 shares at a cost of $7.5/ea and they’re worth ~80¢ each now. Biopharm is dangerous business.
Went in on NMRA and took profits, thank you, jimmi! 🙏
Got in to NMRA at .75 a couple days ago and exited at .95 few minutes ago. Thanks for the play. Had a few other wins from your post Time to subscribe to squeezefinder
NMRA looks primed for a run icl
NMRA is going to squeeze soon 🚀
NMRA squeeze to the moon incoming 🚀
Now i will lean Heavily into just NMRA
Do you see any major catalyst on the horizon? Not sure how long the class suit is going to take? If the decision is favourable to NMRA, then I am anticipating a bounce back purely based on positive news.
There's an ongoing class action lawsuit against NMRA.
There's an ongoing class action lawsuit against NMRA.
Bothe these stocks fkd me up. One bought at 14$ NMRA and SAVA at 4$
I'm hamming on to some based on their pipeline in three works "  Release Details Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update March 3, 2025 PDF Version KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 in Alzheimer’s disease agitation expected by the end of 2025 Expect to progress next M4 positive allosteric modulator (PAM) program into the clinic by mid-2025 Strong financial position with $307.6 million in cash, cash equivalents and marketable securities expected to support operations into mid-2026 WATERTOWN, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. “The first two months of 2025 have been productive for Neumora. We have analyzed the data set provided by KOASTAL-1 and made important amendments to help optimize the ongoing KOASTAL-2 and -3 studies based on the learnings. We believe these changes strengthen the studies and look forward to delivering topline data in 2026. We’ve also progressed enrollment in the Phase 1b signal-seeking study for NMRA-511 in Alzheimer’s disease agitation and expect to advance our next M4 program into the clinic by mid-2025,” said Paul L. Berns, chief executive officer, Neumora. “With our industry-leading pipeline, strong financial position and world class team, we believe we are poised to make a difference for the millions of people living with brain diseases. This will be a productive year for us, and we look forward to providing updates across the pipeline in 2025.” KEY PIPELINE HIGHLIGHTS Neumora is advancing a therapeutic pipeline of seven neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Navacaprant: Optimizing KOASTAL-2 and -3 Studies Based on Learnings from KOASTAL-1 Following the announcement of topline results from the KOASTAL-1 study of navacaprant for the treatment of major depressive disorder (MDD), Neumora conducted extensive analyses to identify factors that might have contributed to the study outcome. These analyses suggested that further optimizing site selection and enhancing medical monitoring are required to help ensure the appropriate patients are enrolled in the KOASTAL program moving forward. Therefore, Neumora has paused KOASTAL-2 and -3 and plans to make the following changes to KOASTAL-2 and -3. The Company plans to resume the KOASTAL-2 and -3 studies in March 2025. Site Selection: The Company reduced the number of clinical sites and selected those sites that we believe have the greatest level of expertise in conducting MDD studies. Medical Monitoring: In addition to the medical monitoring already implemented in the KOASTAL Program, Neumora plans to add the clinician-rated Massachusetts General Hospital Clinical Trials Network and Institute SAFER approach. SAFER is an independent review conducted by clinical psychiatrists to verify the diagnosis and appropriateness of the patient population and ensure that appropriate patients are enrolled in clinical trials. Neumora’s internal medical team will partner with the SAFER clinical team to help ensure patients appropriately meet the eligibility criteria for the studies prior to randomization. Screening Tools: The KOASTAL Program currently uses the Clinical Trial Subject (CTS) database to screen for people who participate in multiple clinical trials. For the ongoing studies, Neumora will add the Verified Clinical Trial (VCT) screening database to complement CTS, with the goal to identify and exclude participants enrolled in multiple clinical studies from enrolling in the KOASTAL studies. The Company expects to report topline data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026. Additionally, Neumora today announced that it has discontinued the Phase 2 clinical trial investigating navacaprant for the treatment of bipolar depression to prioritize the resources allocated to navacaprant on the KOASTAL program. The Company continues to believe that navacaprant may offer benefit for treating bipolar depression and will evaluate opportunities to investigate it in this indication in the future. NMRA-511: On Track to Report Data from Phase 1b Study in Alzheimer’s Disease (AD) agitation by the end of 2025 Neumora is advancing a Phase 1b signal-seeking study investigating NMRA-511 initially in healthy elderly adult participants and then people with agitation associated with dementia due to AD. The Company expects to report topline data from this study by the end of 2025. M4 Positive Allosteric Modulator (PAM) Franchise: Progress next M4 PAM program into the clinic by mid-2025 Neumora’s M4 franchise is comprised of multiple novel compounds that each have different properties and chemical composition and have demonstrated robust activity in preclinical efficacy models as well as high selectivity for the M4 receptor. We believe selective M4 receptor PAMs have the potential to deliver antipsychotic efficacy, while minimizing the side effects associated with current antipsychotics and other non-selective muscarinic agonists."
NMRA, anyone? Green day today is not something regular to see.
Guys, take a look at NMRA. It seems that it's recovering from the latest drop.
The clinical-stage biopharmaceutical company has seven clinical and pre-clinical brain disease programs in its pipeline, with clinical data readouts expected from all three clinical-stage programs in 2025. A key highlight is the ongoing Phase 3 program with navacaprant in depression. The company focuses on developing novel treatments for brain diseases with therapeutically relevant targets and best-in-class pharmacology. Neumora will host a conference call on March 3, 2025, to report Q4 and full-year 2024 financial results and provide a business update. https://www.stocktitan.net/news/NMRA/neumora-therapeutics-announces-leadership-kngux35ykso0.html
Guess we’ll see. I’ve sold 30 contracts that expire 1-17 on NMRA. Strike $10. Sold for just over $4. If I get assigned figured I would sell CC’s against them. If I can sell for $2 then I’ll have a cost basis of $4. What am I missing? (That it drops to $3?) hasn’t bee ln lower than $8 in last year. Seriously. What am I missing?
When you search does NMRA come up? What are other really high IV stocks?
Also- what do you guys think about $NMRA. The IV is insane. You sell $4 contracts at $10 strike price one month out. wtf?!?!?
Where are you finding these? When I searched stocks came up but didn’t include names like $NMRA Not sure why
why doesn't NMRA show up when I search stocks with high IV? Where is the best place to find stocks with high IV?
Will do. Currently balls deep in CSP NMRA and CRVS, 5 and 4 strike, expire January
NMRA currently trading for $10. The January $5 puts are going for $1.50 I sold 10k worth for 3k in premium which will all be profit if the stock doesn’t get cut in half in the next month. Breakeven price is $3.50